PMID- 28746204
OWN - NLM
STAT- MEDLINE
DCOM- 20170807
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 30
DP  - 2017 Jul
TI  - Direct-acting antiviral agent efficacy and safety in renal transplant recipients 
      with chronic hepatitis C virus infection: A PRISMA-compliant study.
PG  - e7568
LID - 10.1097/MD.0000000000007568 [doi]
LID - e7568
AB  - BACKGROUND: The efficacy and safety of direct-acting antivirals (DAAs) for 
      treating hepatitis C virus (HCV)-infected renal transplant recipients (RTRs) has 
      not been determined. METHODS: We searched PubMed, Embase, and the Cochrane 
      Central Register of Controlled Trials and assessed the quality of eligible 
      studies using the Joanna Briggs Institute scale. DAA efficacy and safety were 
      assessed using standard mean difference (SMD) with 95% confidence intervals 
      (95%CIs). RESULTS: Six studies (360 RTRs) were included. Two hundred thirty six 
      RTRs (98.3%) achieved sustained virological response within 12 weeks; HCV 
      infection was cleared in 239 RTRs after 24-week treatment. Liver function 
      differed significantly pre- and posttreatment (alanine aminotransferase, SMD: 
      0.96, 95%CIs: 0.65, 1.26; aspartate aminotransferase, SMD: 0.89, 95%CIs: 0.60, 
      1.18); allograft function pre- and posttreatment was not statistically different 
      (serum creatinine, SMD: -0.13, 95%CIs: -0.38, 0.12; estimated glomerular 
      filtration rate, SMD: 0.20, 95%CIs: -0.11, 0.51). General symptoms (fatigue 
      nausea dizziness or headache) were the most common adverse events (AEs) (39.3%). 
      Severe AEs, that is, anemia, portal vein thrombosis, and streptococcus 
      bacteraemia and pneumonia, were present in 1.1%, 0.6%, and 1.1% of RTRs, 
      respectively. CONCLUSION: Our findings suggest that DAAs are highly efficacious 
      and safe for treating HCV-infected RTRs and without significant AE.
FAU - Chen, Keliang
AU  - Chen K
AD  - Department of Urology, First Affiliated Hospital with Nanjing Medical University, 
      Nanjing, China.
FAU - Lu, Pei
AU  - Lu P
FAU - Song, Rijin
AU  - Song R
FAU - Zhang, Jiexiu
AU  - Zhang J
FAU - Tao, Rongzhen
AU  - Tao R
FAU - Wang, Zijie
AU  - Wang Z
FAU - Zhang, Wei
AU  - Zhang W
FAU - Gu, Min
AU  - Gu M
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Antiviral Agents/adverse effects/*therapeutic use
MH  - Hepatitis C, Chronic/*drug therapy/*surgery
MH  - Humans
MH  - *Kidney Transplantation
PMC - PMC5627830
COIS- The authors declare that they have no competing financial interests. The authors 
      declared that there was no conflict of interest exited.
EDAT- 2017/07/27 06:00
MHDA- 2017/08/08 06:00
PMCR- 2017/07/28
CRDT- 2017/07/27 06:00
PHST- 2017/07/27 06:00 [entrez]
PHST- 2017/07/27 06:00 [pubmed]
PHST- 2017/08/08 06:00 [medline]
PHST- 2017/07/28 00:00 [pmc-release]
AID - 00005792-201707280-00035 [pii]
AID - MD-D-17-02326 [pii]
AID - 10.1097/MD.0000000000007568 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Jul;96(30):e7568. doi: 10.1097/MD.0000000000007568.